Last $11.39 USD
Change Today +0.11 / 0.98%
Volume 2.5K
LZAGY On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
OTC US
Singapore
Frankfurt
OTC US
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

lonza group ag-unspon adr (LZAGY) Snapshot

Open
$11.32
Previous Close
$11.28
Day High
$11.40
Day Low
$11.32
52 Week High
08/29/14 - $11.40
52 Week Low
08/30/13 - $6.83
Market Cap
6.0B
Average Volume 10 Days
12.1K
EPS TTM
--
Shares Outstanding
529.2M
EX-Date
04/22/14
P/E TM
--
Dividend
--
Dividend Yield
2.14%
Current Stock Chart for LONZA GROUP AG-UNSPON ADR (LZAGY)

Related News

No related news articles were found.

lonza group ag-unspon adr (LZAGY) Related Businessweek News

View More BusinessWeek News

lonza group ag-unspon adr (LZAGY) Details

Lonza Group Ltd. supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. It operates in two segments, Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech segment develops and manufactures active pharmaceutical ingredients (APIs) for drug companies; microbial parenteral API, including antibody fragments, vaccines, cytokines, plasmid DNA, fusion proteins, and PEGylated products; and chemical custom services, such as chemically derived active ingredients, antibody drug conjugates, and cytotoxic and peptide syntheses, as well as biological cellular and gene therapies. This segment also offers cell culture, transfection, and molecular biology tools for lifescience research; media used in the production of therapeutics; endotoxin detection assays; products and services targeting cardiovascular, respiratory, neurological, metabolic, cancer, and other disease research areas; and cell biology solutions to enhance efficiencies in research. This segment serves customers in academic and government institutions, and in biotech and pharmaceutical organizations. The Specialty Ingredients segment offers personal care and preservation products comprising actives for antidandruff shampoos, and natural and organic cosmetic ingredients; vitamin B3 compounds and L-Carnitine, as well as nutritional ingredients used in pharmaceuticals, human energy drinks, and animal feeds; and microbial control solutions, including disinfectants and sanitizers that protect from dangerous and unwanted microbes. This segment also provides custom agricultural manufacturing services to enhance crop yields; sanitizers and other treatment chemicals, as well as feeder systems for drinking water disinfection and surface-water treatments; industrial Solutions, such as preservatives and biocide blends; and products and services that enhance the quality of wood. The company was founded in 1897 and is headquartered in Basel, Switzerland.

9,761 Employees
Last Reported Date: 07/24/14
Founded in 1897

lonza group ag-unspon adr (LZAGY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

lonza group ag-unspon adr (LZAGY) Key Developments

Lonza Group Ltd Reports Unaudited Earnings Results for the Six Months Ended June 30, 2014; Reiterates Earnings Guidance for the Year of 2014

Lonza Group Ltd. reported unaudited earnings results for the six months ended June 30, 2014. For the period, the company reported sales of CHF 1,800 million compared to CHF 1,744 million a year ago. EBIT was CHF 215 million compared to CHF 112 million a year ago. Profit before income taxes was CHF 174 million compared to CHF 49 million a year ago. Profit for the period, attributable to the equity holder of the parent was CHF 140 million or CHF 2.68 per diluted share compared to CHF 41 million or CHF 0.79 per diluted share a year ago. Net cash provided by operating activities was CHF 163 million compared to CHF 101 million a year ago. Purchase of property, plant & equipment and intangible assets was CHF 70 million compared to CHF 86 million a year ago. Net purchase of other assets was CHF 4 million compared to CHF 9 million a year ago. EBITDA was CHF 362 million compared to CHF 334 million a year ago. Operational free cash flow was CHF 124 million compared to CHF 68 million a year ago. Net debt as at June 30, 2014 was CHF 2,113 million compared to CHF 2,417 million a year ago. Core EBITDA was CHF 368 million compared to CHF 346 million a year ago. Core result from operating activities was CHF 241 million compared to CHF 213 million a year ago. Core profit for the period was CHF 162 million or CHF 3.10 per diluted share compared to CHF 127 million or CHF 27 per diluted share a year ago. Core RONOA was 14.5% compared to 11.8% a year ago. RONOA was 10.5% compared to 6.6% a year ago. The company reiterated its full-year 2014 outlook with a core EBIT growth of 10% and sales growth of 5%. The capital expenditure in 2014 will remain well below CHF 300 million.

Lonza Group Ltd, H1 2014 Earnings Call, Jul 24, 2014

Lonza Group Ltd, H1 2014 Earnings Call, Jul 24, 2014

Lonza Invests in Singleuse Technology and Facility Upgrades for Clinical ADC Manufacturing

Lonza announced investment plans for technology and facility improvements to its Antibody Drug Conjugate (ADC) clinical manufacturing facility in Visp, Switzerland. The planned upgrades include the introduction of single-use technology for flexible ADC manufacturing, along with a recently optimized plant layout and revamping of the Heating, Ventilation, Air Conditioning systems, which has resulted in a larger ADC production area. The addition of single-use manufacturing systems will reduce potential product contamination risks and allow for increased manufacturing capacity of existing and novel ADC platforms. Currently, Lonza's clinical ADC plant in Visp produces toxicology lots, early-phase GMP lots and GMP re-supply lots to support ongoing clinical trials for several different product candidates. Oncology therapeutics represents one of the fastest-growing segments of the pharma and biotech industry, and the deployment of ADC targeted therapies has intensified in recent years. This growth has led to an increased clinical pipeline, which necessitated the expansion of manufacturing capacity and the utilization of new single-use technologies. ADC cGMP manufacturing facilities must be designed to handle both biological species and highly potent cytotoxic small organic molecule drugs. The Visp site will continue to offer integrated end-to-end development and manufacturing of ADCs, including the cytotoxic small organic molecules used in these products and all associated analytics. All current operations will continue without interruption.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LZAGY:US $11.39 USD +0.11

LZAGY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albemarle Corp $63.58 USD +0.37
Clariant AG SFr.16.16 CHF +0.02
K+S AG €23.55 EUR -0.39
Symrise AG €40.60 EUR -0.045
Wacker Chemie AG €90.30 EUR +0.81
View Industry Companies
 

Industry Analysis

LZAGY

Industry Average

Valuation LZAGY Industry Range
Price/Earnings 28.6x
Price/Sales 1.5x
Price/Book 2.5x
Price/Cash Flow 28.9x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LONZA GROUP AG-UNSPON ADR, please visit www.lonza.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.